Detailed price information for Scienture Holdings Inc (SCNX-Q) from The Globe and Mail including charting and trades.
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.
Scienture Holdings Inc. (NASDAQ:SCNX) on Friday announced that three leading U.S. pediatric academic medical centers added its proprietary hypertension medication to their formularies. These specialized hospitals, which focus on treating children with severe and chronic medical conditions, now offer Arbli (losartan potassium) Oral Suspension, 10 mg/mL to their patients. “The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as w
Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock split.
Detailed price information for Scienture Holdings Inc (SCNX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.